REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 191 filers reported holding REVANCE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,987 | -50.3% | 4,533 | +9.7% | 0.00% | – |
| Q2 2023 | $104,547 | -12.2% | 4,131 | +11.7% | 0.00% | – |
| Q1 2023 | $119,109 | +81.3% | 3,698 | +2.7% | 0.00% | – |
| Q4 2022 | $65,692 | -27.0% | 3,600 | +8.3% | 0.00% | – |
| Q3 2022 | $90,000 | +130.8% | 3,324 | +17.1% | 0.00% | – |
| Q2 2022 | $39,000 | -30.4% | 2,838 | 0.0% | 0.00% | – |
| Q1 2022 | $56,000 | +93.1% | 2,838 | +60.6% | 0.00% | – |
| Q4 2021 | $29,000 | -51.7% | 1,767 | -19.0% | 0.00% | – |
| Q3 2021 | $60,000 | -7.7% | 2,182 | -1.5% | 0.00% | – |
| Q2 2021 | $65,000 | +18.2% | 2,216 | +12.2% | 0.00% | – |
| Q1 2021 | $55,000 | -5.2% | 1,975 | -4.0% | 0.00% | – |
| Q4 2020 | $58,000 | -1.7% | 2,057 | -12.9% | 0.00% | – |
| Q3 2020 | $59,000 | +51.3% | 2,362 | +46.3% | 0.00% | – |
| Q2 2020 | $39,000 | +5.4% | 1,615 | -33.2% | 0.00% | – |
| Q1 2020 | $37,000 | – | 2,419 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NovaQuest Capital Management, L.L.C. | 1,558,426 | $48,000,000 | 65.50% |
| Essex Woodlands Management, Inc. | 3,842,047 | $118,335,000 | 25.90% |
| Rhenman & Partners Asset Management AB | 203,181 | $6,258,000 | 0.77% |
| EAM Global Investors LLC | 44,898 | $1,383,000 | 0.72% |
| Fosun International Ltd | 319,313 | $9,835,000 | 0.62% |
| EAM Investors, LLC | 113,096 | $3,483,000 | 0.58% |
| ArrowMark Colorado Holdings LLC | 1,735,699 | $53,460,000 | 0.53% |
| Perceptive Advisors | 618,957 | $19,064,000 | 0.53% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 111,360 | $3,430,000 | 0.45% |
| Schonfeld Strategic Advisors LLC | 83,700 | $2,578,000 | 0.19% |